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Background: Epstein-Barr virus (EBV)-related malignancies harbour distinct serological responses to EBV antigens.
We hypothesized that EBV serological patterns can be useful to identify different stages of chronic lymphocytic
leukemia.
Methods: Information on 150 cases with chronic lymphocytic leukemia and 157 frequency-matched (by age,
sex and region) population-based controls from a Spanish multicentre case-control study was obtained. EBV
immunoglobulin G serostatus was evaluated through a peptide-based ELISA and further by immunoblot analysis
to EBV early antigens (EA), nuclear antigen (EBNA1), VCA-p18, VCA-p40 and Zebra. Two independent individuals
categorized the serological patterns of the western blot analysis. Patients with very high response and diversity in
EBV-specific polypeptides, in particular with clear responses to EA-associated proteins, were categorized as having an
abnormal reactive pattern (ab_EBV). Adjusted odds ratios (OR) and 95% confidence interval (CI) were estimated using
logistic regression models.
Results: Almost all subjects were EBV-IgG positive (>95% of cases and controls) whereas ab_EBV patterns were
detected in 23% of cases (N = 34) and 11% of controls (N = 17; OR: 2.44, 95% CI, 1.29 to 4.62; P = 0.006), particularly in
intermediate/high risk patients. Although based on small numbers, the association was modified by smoking with a
gradual reduction of ab_EBV-related OR for all Rai stages from never smokers to current smokers.
Conclusions: Highly distinct EBV antibody diversity patterns revealed by immunoblot analysis were detected in
cases compared to controls, detectable at very early stages of the disease and particularly among non smokers.
This study provides further evidence of an abnormal immunological response against EBV in patients with chronic
lymphocytic leukemia.
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The gamma-herpes Epstein-Barr virus (EBV) infects and
persists in human B-cells by exploiting the B-cells envir-
onment to maintain its life cycle and by avoiding the
host’s immune surveillance with limited expression of
viral proteins [1]. Healthy EBV carriers display anti-EBV
antibodies to only a limited number of EBV proteins, in-
cluding Esptein-Barr nuclear antigen 1 (EBNA1), viral
capsid antigen (VCA)-p18, VCA-p40 (BdRF1) and Zebra
(BZLF1) whereas a small proportion of healthy carriers
with subclinical virus reactivation produces antibodies to
early antigen (EA) [1]. Contrary, high anti-VCA and
anti-early antigen-diffuse (EAd) titers have been ob-
served in EBV related malignancies such as Hodgkin
lymphoma and nasopharyngeal carcinoma [2] but the
role of EBV in chronic lymphocytic leukemia (CLL) re-
mains unclear [3-6].
Despite CLL malignant cells being generally EBV
negative, EBV has been proposed to play an indirect role
in the genesis or progression of CLL [5,7,8]. Data on
EBV serological biomarkers is sparse [3-6]. Using data
from the European case-control study EpiLymph, de
Sanjose et al found that CLL patients were 3 times more
likely to have an aberrant EBV antibody pattern
(ab_EBV), mainly reflected by excessively high EA re-
sponse, than controls, while no association with other
lymphoma subtypes was observed [5]. Patients with
ab_EBV were characterized by a more diverse pattern of
antibody reactivity, yielding a broadly reactive immuno-
blot profile. In a nested case-control study within the
Physicians’ and Nurses’ Health Studies, CLL patients
showed a pattern also suggestive of an aberrant viral
replication indicated by elevated anti-EBNA2 and anti-
VCA and a EBNA1/EBNA2 ratio less than or equal to 1
compared to controls [3]. Similarly, de Roos et al exam-
ined the prospective antibody response to anti-VCA,
EBNA1, EAd using multiplex technology and EBV DNA
load samples collected before diagnosis in 142 CLL/
prolymphocytic leukemia patients and their matched
controls [4]. A lower EBNA1 response with high
levels of both EBV DNA and anti-EAd antibodies were
associated with an increased risk of CLL [4]. In a recent
prospective study increased EAd and Zebra anti-
bodies were observed in CLL cases although based
on a limited series [6]. Mental and medical (such as use
of corticosteroids) “stressors” have been strongly impli-
cated in the reactivation from the EBV latent stage to a
lytic stage [9-11] and steroids are used to control nau-
sea or as part of some CLL treatments. Smoking as also
being associated with EBV seropositivity and reactiva-
tion of EBV [12] but not with CLL [13-15]. Here, we
hypothesized that EBV serological patterns differ by dif-
ferent stages of chronic lymphocytic leukemia. Using
data from the Spanish CLL multicentric case-control(MCC-Spain), the present work looked at the sero-
logical patterns to EBV and its association with Rai
stages and potential effect modifications from epidemio-
logical questionnaire in CLL cases and their respective
controls.
Materials and methods
The Spanish multicase-control study (MCC-Spain study,
www.mccspain.org)
Cases were recruited within the MCC-Spain study and
in collaboration with the International Cancer Genome
Consortium on Chronic Lymphocytic Leukemia Project
(ICGC-CLL, www.cllgenome.es and www.icgc.org). The
main objective of the MCC-Spain study is to investigate
lifetime environmental, infectious, medical and occupa-
tional exposures, and genetic factors associated with 5
cancer sites. In brief, the recruitment took place between
March 2010 and July 2012 and includes pathological
confirmed cases of CLL enrolled in 11 hospitals of 5
Spanish areas (Asturias, Barcelona, Cantabria, Girona
and Granada), together with a common set of frequency-
matched population controls, randomly selected from
lists of primary care centres. Response rate for CLL was
87% and for controls with valid phone number response
rates were 48%, 58% and 60% for Asturias, Barcelona
and Cantabria, respectively. Information was requested
through a computerized face-to-face interview (the ques-
tionnaire is available at www.mccspain.org). A signed
consent form was requested for acceptance of analysis of
biological material and verification of clinical informa-
tion. Ethical approval was granted for each participating
centre of the study.
Study participants
We calculated that a sample size of 150 case-control
pairs would be required to detect a minimum odds ratio
of 3.0 [5] with alpha level 0.05 and 95% statistical power.
Finally, 150 cases and 157 controls were enrolled in the
present study (7 EBV-tested cases were dropped due to
invalid diagnosis). Both newly diagnosed and prevalent
cases were included in the study. Given the indolent
course of the disease, incident cases were defined as
newly diagnosed patients with CLL that have been re-
cruited within 1 year of diagnosis and the remainders
were classified as prevalent cases.
Outcome definition
CLL cases were diagnosed according to the criteria of
the International Workshop on Chronic Lymphocytic
Leukemia [16]. All diagnoses were morphologically and
immunologically confirmed using flow cytometry immu-
nophenotype and complete blood count. Disease severity
was evaluated using the Rai staging system obtained at
the time of interview from medical records and verified
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were categorised into two groups: A) low risk cat-
egory including asymptomatic patients with lympho-
cytosis only (Rai 0) and B) intermediate/high risk
category including patients with lymphocytosis with
or without lymphadenopathy, hepatomegaly, spleno-
megaly, anemia and/or thrombocytopenia (Rai I-IV).
CLL and small lymphocytic lymphoma (SLL) were
considered the same underlying disease [17].EBV serology
The serological analysis was performed at the Depart-
ment of Pathology, VU medical centre Amsterdam, The
Netherlands. Laboratory methods have been described
in detail elsewhere [5].
ELISA: For the assessment of the general EBV serosta-
tus, we used synthetic peptide-based ELISA assays that
measure IgG reactivity to combined immunodominant
epitopes of EBNA1 (BKRF1) and VCA-p18 (BFRF3)
respectively.
Immunoblot analysis: Nuclear extracts of the TPA/
butyrate induced HH514.C16 cells were used as
source of antigen in immunoblot assays, using stan-
dardized procedures as described previously [5]. Dis-
tinct antibody diversity patterns revealed by the
immunoblot analysis allowed us to categorize subjects
according to their EBV overall expression, as defined
before [5]. Uncomplicated EBV carriers are character-
ized by restricted IgG antibody reactivity to a limited
number of EBV proteins. Besides EBNA1 and VCA18,
the VCA-p40 (BdRF1) and Zebra (BZLF1) proteins
are generally recognized by healthy individuals. Pa-
tients with infectious mononucleosis (IM) are recog-
nized by a strong response to EAd polypeptides
encoded by BMRF1 (EAd-p47/54) and BALF2 (EAd-
p138), in the absence of EBNA1 reactivity (IM-pattern).
Patients with active EBV infection and ab_EBV activ-
ity are characterized by a more diverse pattern of
antibody reactivity, yielding a broadly reactive immu-
noblot profile. For statistical analysis, immunoblot re-
sults were grouped into 2 categories, being normal
(pattern 1) or abnormal reactive pattern or ab_EBV
(pattern 2) (Additional file 1: S1). Patients with an IM-
like result were coded as ab_EBV positive, as published
before [5]. Individual bands on immunoblot strips were
scored independently by 2 individuals according to re-
activity from negative to 3+, standardized by reference to
a set of control sera analysed in each immunoblot experi-
ment. EBV seropositivity is defined by a positive re-
sponse in either VCA-p18 and/or EBNA1 IgG ELISA
and a positive score in the EBV-immunoblot. Serum sam-
ples from cases and controls were tested blind to their dis-
ease status.Statistical analysis
Odds ratios (OR) were estimated by maximum likeli-
hood using unconditional logistic regression to examine
the association between ab_EBV and CLL. Polytomous
unconditional logistic regression models were used to
compare each CLL stage to controls. All models were
adjusted for the frequency matched variables: age (based
on tertile distribution of controls: <63, 63-71, 72 or more
years), sex and centers (Barcelona, Other). None of the
adjustment variables had missing values. Ninety-five per-
cent confidence intervals (CI) for adjusted OR were de-
rived from the variance-covariance matrix of the logistic
regression estimators. Potential confounding variables
were examined comparing if the unadjusted effect meas-
ure differs from the adjusted measure by 10%. The con-
tribution to the models to effect modifications was
tested by means of likelihood-ratio tests. A priori se-
lected variables included basic socio-economic factors
(age at recruitment, region, sex, body mass index
coded as normal: 18.0 to 24.9 kg/m2, overweight: 25
to 29.9 kg/m2 and obese: ≥30 kg/m2, education, tobacco
consumption, personal history of non-haematological
cancer) as well as established risk factor for CLL (family
history of haematological cancer) and factors that might
be associated with EBV infection (number of siblings
coded as 0-1, 2-3 and 4 or more). Alcohol could not be
examined due to a high percentage of missing values
among controls (12%) and cases (42%). In fully adjusted
models, missing values for each adjustment variable were
treated as a separate category. A forest plot of the effect
modification of smoking on the relation between CLL
and ab_EBV was done with black squares indicating OR
and vertical lines representing 95% CI. All tests for inter-
actions were made on a multiplicative scale.
Sensitivity analyses were performed comparing pa-
tients with different length of time from diagnosis to re-
cruitment (incident versus prevalent) as well as excluding
individuals self-reporting gluco-corticosteroid medications.
All P-values were two-sided and data analyses were per-
formed using STATA computer software (version 10.1).
Results
EBV carriership defined by IgG reaction in both the
VCA-p18 and EBNA1 ELISA was detected in 98%
(N = 302/307) of the 307 individuals included in the
analysis. EBV seronegativity was reported for 1 control
and 4 cases. Descriptive statistics of the 150 cases (96
CLL Rai 0, 53 CLL Rai I-IV and 1 patient with unknown
Rai stage) and 157 controls are shown in Table 1. Most
participants were from Barcelona (≈85% of controls) with
a mean age for cases and controls of 67 (standard devi-
ation: 10 years) and around 65% of patients with male
sex. Overall, there were no statistically significant differ-
ences in the distribution between cases and controls with
Table 1 Socio-demographic and other descriptive
characteristics of cases and controls
CONTROLS CASES CLL Rai0 CLL Rai I-IV
N 157 150b 96 53
Region
Barcelona 133 (85%) 129 (86%) 86 (90%) 43 (81%)
Other 24 (15%) 21 (14%) 10 (10%) 10 (19%)
P-valuea - 0.75 0.27 0.54
Age group
<63 48 (31%) 44 (29%) 22 (23%) 22 (42%)
63-71 55 (35%) 53 (35%) 38 (40%) 15 (28%)
72+ 54 (34%) 53 (35%) 36 (38%) 16 (30%)
mean (SD) 67 (10) 67 (10) 68 (9) 65 (11)
P-valuea - 0.81 0.29 0.24
Sex
Male 102 (65%) 97 (65%) 64 (67%) 32 (60%)
Female 55 (35%) 53 (35%) 32 (33%) 21 (40%)
P-valuea - 0.96 0.78 0.55
Education
Incomplete primary
school
49 (31%) 53 (38%) 34 (39%) 19 (37%)
Complete primary
school
40 (25%) 47 (33%) 31 (35%) 15 (29%)
Pre-university/technical
studies
45 (29%) 25 (18%) 13 (15%) 12 (23%)
University 23 (15%) 16 (11%) 10 (11%) 6 (12%)
P-valuea - 0.08 0.05 0.75
Tobacco consumption
Never 72 (46%) 68 (46%) 42 (45%) 26 (49%)
Former 59 (38%) 61 (41%) 40 (43%) 20 (38%)
Current 25 (16%) 18 (12%) 11 (12%) 7 (13%)
P-valuea - 0.60 0.57 0.87
Number of siblings
0/1 39 (25%) 24 (17%) 14 (16%) 10 (19%)
2 or 3 69 (44%) 57 (41%) 36 (41%) 21 (40%)
4+ 49 (31%) 59 (42%) 37 (43%) 21 (40%)
P-valuea - 0.10 0.13 0.45
Body mass index
Normal 51 (34%) 35 (28%) 21 (27%) 13 (28%)
Overweight 77 (52%) 69 (55%) 45 (58%) 24 (51%)
Obese 21 (14%) 22 (17%) 12 (15%) 10 (21%)
P-valuea - 0.45 0.53 0.44
Personal history of other cancer
Never 135 (87%) 119 (84%) 77 (88%) 42 (81%)
Ever 21 (13%) 22 (16%) 11 (13%) 10 (19%)
P-valuea - 0.60 0.83 0.31
Table 1 Socio-demographic and other descriptive
characteristics of cases and controls (Continued)
Family history of haematological cancer
No 121 (92%) 119 (89%) 70 (85%) 48 (94%)
Yes 10 (8%) 15 (11%) 12 (15%) 3 (6%)
P-valuea - 0.33 0.11 0.67
CLL: Chronic lymphocytic leukemia; N: Number; SD: standard deviation.
a: All p-values were for heterogeneity except for the age variable with a P-value
for trend. b: Rai stage was unknown for one patient.
Numbers do not add up to total number in all instances due to missing value.
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bacco consumption, body mass index, number of siblings
and personal history of other cancer.
As shown in the table of Additional file 1: S2, among
controls, the prevalence of ab_EBV patterns decreased
with increasing age (P-trend = 0.02). Current smokers
were more likely to have aberrant EBV patterns than
never or past smokers (P-heterogeneity < 0.001) and no
difference was observed in relation to other examined
variables. In summary, no confounding variable between
the presence of CLL and ab_EBV patterns was identified.
Hence, results were further adjusted only for the
frequency-matched variables: age, sex and region.
Table 2 shows odds ratio for all cases and by CLL Rai
stages in relation to ab_EBV patterns adjusted for age,
sex and region. Overall, cases were twice more likely
to have ab_EBV patterns than controls (23% of cases
versus 11% of controls; OR: 2.44, 95% CI: 1.29 to
4.62; P = 0.006) but when Rai stages were considered,
Ab_EBV reactivity was significantly increased only in CLL
Rai I-IV, irrespective of treatment status (P-heterogeneity
treated versus untreated CLL Rai I-IV: 0.26).
Of the epidemiological characteristics examined
(Additional file 1: S2), only smoking status modifiedTable 2 Odds ratios of chronic lymphocytic leukemia for
aberrant EBV patterns
N N (%) ab_EBV
positive
ORa (95%CI) P-value
Controls 157 17 (11%) REF
Overall
All cases 150 34 (23%) 2.44 (1.29 to 4.62) 0.006
By Rai stages
CLL Rai 0 96 16 (17%) 1.67 (0.79 to 3.51) 0.18
CLL Rai I-IV
(untreatedb)
37 11 (30%) 3.25 (1.35 to 7.82) 0.008
CLL Rai I-IV
(treatedb)
16 7 (44%) 7.33 (2.33 to 23.06) 0.001
Ab_EBV: aberrant EBV pattern; CLL: Chronic lymphocytic leukemia; CI: confidence
interval; N: Number; OR: Odds ratio; REF: reference group. a: Logistic regression for
overall analysis on cases and controls, multinomial logistic regression otherwise.
Odds ratios adjusted for age, sex and region. b: treated for CLL.
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interaction between never, former and current smokers:
P = 0.005). Overall, a gradual decrease in odds ratios from
never, former to current smokers was observed (Figure 1).
A strong positive association between ab_EBV and CLL
was detected in never smokers (OR for all cases: 6.75,
95% CI: 2.10, 21.71; P = 0.001), irrespective of Rai stages
and treatment (Additional file 1: S3), whereas, albeit in
small numbers, cases being current smokers were 0.3
times less likely to have ab_EBV patterns than controls
currently smoking (OR for all cases: 0.34, 95% CI: 0.07,
1.66, P = 0.18). A borderline statistical significant inter-
action with age was found (P = 0.07).
To examine if serological response could be related to
the inclusion of prevalent cases with existing condition
for a period of time longer than one year, sensitivity ana-
lyses were performed but no modification of the findings
was observed (Additional file 1: S4). The mean time be-
tween diagnosis and recruitment into the study was
2.57 years (standard deviation: 2.97 years and range:
0 year to 16.72 years). The fully adjusted model includ-
ing the nine variables selected a priori gave similar
results (OR: 2.54, 95% CI: 1.27 to 5.08; P-value: 0.008).
Upon exclusion of individuals self-reporting gluco-
corticosteroid medications (N = 5 and N = 8 for controls
and cases, respectively) the results were unchanged (data
not shown).Figure 1 Association between chronic lymphocytic leukemia
and aberrant EBV patterns, by smoking status. Ab_EBV: aberrant
EBV pattern; CLL: Chronic lymphocytic leukemia; CI: confidence
interval; OR: Odds ratio; N: Total number; %pos: proportion with
aberrant patterns.a: Logistic regression adjusted for age, sex and
region. b: All tests for interactions were made on a multiplicative scale.Discussion
Using immunoblot analysis, the present study showed
that patients with CLL compared to controls had mark-
edly distinct pattern in EBV-specific polypeptides, in
particular clear responses to EA-associated proteins. Al-
though based on small numbers, the association was
modified by smoking status with significantly higher
ab_EBV-related OR for all CLL stages in never smokers
than in current smokers.
Ab_EBV pattern was strongly associated with CLL
suggesting an increased viral replication or loss of host
control infection [3-5]. Our results were supported by
those from the European study EpiLymph that used the
same immunoblot technique. [5] In line with our find-
ings, using multiplex technology, previous studies re-
ported an increased risk in patients with higher levels
of antibody to EAd [4,6] but also with EBV DNA loads,
both markers of EBV reactive infections [4]. Bertrand
et al reported non-significant associations with ele-
vated titers against EBV EBNA-2 and VCA, and EBNA1/
EBNA-2 ratio less than or equal to 1, but no differences
in the titers against EBV-EA prior to diagnosis were ob-
served in 79 CLL compared to those in a set of matched
controls [3].
Since CLL cells are generally EBV negative, a direct
role of EBV in the aetiology of CLL seems unlikely. We
speculate that the increased ab_EBV could also corres-
pond to a response of the B-cell repertoire to replace
“sick” lymphocytes (CLL cells) which in turn results with
the expansion of latently infected B cells. If further re-
search can confirm this hypothesis, the ab_EBV pattern
could then be interpreted as a reactive response that is
downplayed among current smokers. Further, ab_EBV
reactivation may, in turn, trigger both B- and T-cell
activation, which may increase the risk of uncontrolled
lymphoproliferations and, hence, higher probability of
transforming mutations. Lifetime exposure to infectious
agents [18-22] causing a strong and inappropriate
immune response or through persistent and chronic anti-
gen stimulation have been suggested to trigger monoclonal
B-cell lymphocytosis (MBL), a precursor to CLL and CLL
development. EBV could as well be one of the pathogens
involved in the indirect deregulation of B-cells. However,
as ever in a retrospective study design, a reverse causality
bias could not be excluded: the presence of ab_EBV pat-
terns could reflect an existing inefficient immune system of
CLL patients.
Of particular interest is the evidence suggesting that
the association between ab_EBV patterns and CLL is
modified by tobacco smoke. This interaction might pro-
vide an explanation for some inconsistencies across
publications related to EBV serology. To date and in ac-
cordance to our data, large cohort studies [13,14] and
pooled case-control studies [15], comparing the risk of
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no association. EBV infects, persists in human B-cells
and reactivates in epithelial cells of the naso- and oro-
pharynx during lytic reactivation and transmission via
saliva [23]. This direct exposure to tobacco compounds
could modulate the life cycle of the virus. The regulation
of EBV infection by the host necessitates efficient T-
cell–mediated immunity and tobacco smoke has been
related to changes in both humoral and cell-mediated
immune responses [24]. In particular, chronic inflamma-
tion via cytokine production is thought to play an im-
portant role in CLL [25] and smoking might affect
further the deregulation of inflammatory pathways and
T-cell mediated immunity [24] and counterbalance the
serological association between EBV and CLL. Further-
more, smoking was recently confirmed as a risk factor
for nasopharyngeal carcinoma, a cancer etiologically
closely related to aberrant EBV infection in certain pop-
ulations [12].
Limitations of our study include the small sample size
that does not allow detailed examination of the interac-
tions between EBV results and smoking in CLL, overall
and by disease severity. The updated guidelines for the
classification of CLL and MBL [16,26] have had a huge
impact on the overall classification of CLL, reducing the
burden of CLL in about 45% [27,28]. Unfortunately, CLL
Rai 0 could not be disentangled from MBL patients
since, for most patients, the absolute B-cell count was
unknown at recruitment. Another limitation of the study
was the inclusion of prevalent cases [29]. However, inci-
dent and prevalent cases did not appear to differ with re-
spect to ab_EBV patterns and the exclusion of prevalent
cases did not affect the overall results. Finally, the main
advantage of the MCC-Spain study is the recruitment of
controls from the general population.
In conclusion, ab_EBV pattern is present in early
stages of CLL and is modulated by smoking status. Our
data suggest that ab_EBV pattern is likely to reflect a
disease response to an existing deficient B-cell pool in
CLL rather than a carcinogenic role. Exposure to to-
bacco smoke should be carefully examined for future
studies investigating EBV circulating biomarkers.Additional file
Additional file 1: S1 - Immunoblot EBV reactive patterns. S2 - Odds
ratios (OR) and 95% confidence interval (CI) for CLL, by various characteristics.
S3 - Odds ratios of CLL by Rai stages for aberrant EBV patterns, stratified by
tobacco consumption S4 - Odds ratios of CLL for aberrant EBV patterns, by
different prevalence time periods.Abbreviations
ab_EBV: Aberrant Esptein-Barr virus; CLL: Chronic lymphocytic leukemia;
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